Lipoprotein(a), a human serum iipoprotein structuraily related to low-density iipoprotein (LDL), contains in addition to apoiipoprotein B (apo B) apolipoprotein(a) [apo(a)], a glycoprotein with a strong homoiogy to plasminogen. Lp(a) is a risk factor for coronary heart disease and ischemic cerebrovascuiar disease. Several immunological techniques are used to quantify Lp(a) in human serum, including radioimmunoassays, rocket immunoelectrophoresis, and enzyme-linked immunosorbent assays. Only the last method is suitable for large-scale clinical studies. We describe another solid-phase immunoassay, based on the dissociation-enhanced lanthanide fluorescence system Delfia#{174} (Waliac Oy), and outline the technical details. A polyclonal antiserum directed against Lp(a) was used as the capture antibody. Two kinds of detection antibodies were applied, a polyclonal antiserum against apo B and the polyclonalantiserum against Lp(a). in plasma (14) . Eleven polymorphic forms of apo(a) have been reported by others (15) . Furthermore, a partial amino acid sequence of human apo(a) is homologous to plasminogen (16, 17), but apo(a) is not capable of cleaving fibrin (17) . Amidolytic activity is associated with apo(a) (18, 19) , but fibronectin acts as the natural substrate (19). In the search for the biochemical mechanisms responsible for the atherogenicity of Lp(a), some have suggested that Lp(a) may act as an interloper in the fibrinolytic system (20, 21 
Increased serum concentrations
of Lp(a) correlate positively with angiographically documented coronary heart disease (1, 2) and indicate high risk for myocardial infarction, even at a young age (3). Moreover, individuals with increased concentrations of Lp(a) have a higher risk of ischemic cerebrovascular diseases (4) (5) (6) (7) . Lp(a) concentration is also a predictor of vein-graft stenosis after coronary artery bypass surgery; Lp(a) was detected immunochemically in coronary artery bypass vein grafts resected at re-operation (8, 9). Therapy with hydroxymethylglutaryl-CoA reductase inhibitors such as lovastatin or simvastatin has in some cases led to an increase in concentrations of Lp(a) in serum (10, 11).
Monitoring

Lp(a) concentrations during this therapy is
recommended.
Lp(a) is a low-density lipoprotein (LDL)-like particle, fide bridge with apolipoprotein(a) [apo(a)J (12), and contains specific antigenic sites (13) . There are six isoforms of apo(a), differing in molecular mass and genetics, resulting in Lp(a) glycoprotein phenotypes with different Lp(a) concentrations in plasma (14) . Eleven polymorphic forms of apo(a) have been reported by others (15) . Furthermore, a partial amino acid sequence of human apo(a) is homologous to plasminogen (16, 17) , but apo(a) is not capable of cleaving fibrin (17) . Amidolytic activity is associated with apo(a) (18, 19 ), but fibronectin acts as the natural substrate (19) . In the search for the biochemical mechanisms responsible for the atherogenicity of Lp(a), some have suggested that Lp(a) may act as an interloper in the fibrinolytic system (20, 21 (5) .
Screening for Lp(a) is done with electrophoresis (30).
A comparison of the characteristics of the immunological assays for Lp(a) was published recently (31) . Here we present an Eu3-based fluorescence immunoassay (Eu-FIA) of Lp(a) used in the Delfia#{174} system. This is a quick, accurate, and reliable assay of normal and pathological concentrations of Lp(a) in large-scale studies.
Materials and Methods FluorescenceImmunoassay
The principle of time-resolved fluorometry was de- 
Statistical Evaluation
Linear-regression analysis was performed with a Hewlett-Packard (Palo Alto, CA) HD-41 CX.
Results and DiscussIon
The rocket immunoelectrophoresis and the radioimmunoassays used in the majority of clinical studies are not suitable for large-scale Lp(a) determination. Enzyme-linked immunoassays (26, 27) and the Eu-FIA, as presented here, offer advantages over these methods. We compared the FIA with rocket immunoelectrophoresis, because the latter method was well established in our laboratory and has been used to measure Lp(a) concentration in many studies (1, 3, 4, 6, 7, 9-11) . Moreover, we wanted to determine whether fixing Lp(a) onto a solid phase with antibody, as in a sandwich assay, could influence the quantification of Lp(a) as compared with immunoprecipitation in a gel, the method on which rocket immunoelectrophoresis is based.
Measuring
Lp(a) concentrations by using antibodies specific for apo(a) and expressing the results in terms of the total lipeproteun mass do not take into account the variations in ape(a) isoforms (36). The apo(a)/apo B mass ratio could be in the range 0.5-1.3 (37) . However, only one copy of ape B is thought to be in each Lp(a) We also compared the rocket immunoelectrophoresis and the Eu-FIA by using anti-Lp(a) as the capture antibody and as the detection antibody (Figure 1, bottom) . We obtained a good correlation between the two methods (r = 0.965). However, for Lp(a) values between 150 and 350 mg/L, there was a shift toward Eu-FIA values being greater than those from the rocket immunoelectrophoresis.
This shift was not seen with anti-ape B as the detection antibody (Figure 1, top) .
In a third series of Lp(a) determinations, we used anti-Lp(a) as the capture antibody and anti-ape B as the detection antibody and compared the results with those obtained with anti-Lp(a) as both the capture and the detection antibody (Figure 2 ). For this comparison, r = 0.973.
The standard curves for Eu-FIA with anti-Lp(a) as capture antibody and anti-ape B or anti-Lp(a) as detection antibody are depicted by logarithmic plotting in Figures 3A (left and right) aF isoform of Lp(a) added at 57, 114, 228, and 456 mg/L;n = 6.
5F
Isoform of Lp(a) added at 55.5, 105, 210, and 420 mg/L; n = 6. recommend using the anti-Lp(a) antiserum as the capture antibody and the anti-apo B as the detection antibody. This combination agreed best with the values obtained by rocket immunoelectrophoresis in the diagnostically important range of 150-350 mgfL. In addition, the potential cross-reactivity of anti-Lp(a) antiserum with plasminogen can be eliminated as previously recommended (27) .
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